iOrganBio, an innovator in intelligent cell manufacturing, announced today the appointment of Jessica Owens to its Board of Directors. Owens brings over 20 years of experience in building and scaling companies at the intersection of life sciences, health technology, and AI. She co-founded GRAIL, a healthcare company that raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson. She also serves as co-founder and General Partner at Initiate Ventures.
iOrganBio is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company's core technology, CellForge, is an AI-powered platform that uses automation and real-time adjustments to guide cell development. At the heart of CellForge is the functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
According to iOrganBio, Owens' counsel will be invaluable as the company scales CellForge, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. The appointment underscores iOrganBio's commitment to integrating AI and life sciences expertise to accelerate disease modeling, regenerative medicine, and drug development.
For more information about iOrganBio and its technology, visit iOrgan.Bio or follow the company on LinkedIn.
